索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]李梓晗,刘园桥,司道远.甲状腺激素治疗心力衰竭的研究进展[J].国际心血管病杂志,2024,02:93-96,100.
点击复制

甲状腺激素治疗心力衰竭的研究进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年02期
页码:
93-96,100
栏目:
综述
出版日期:
2024-03-25

文章信息/Info

Title:
-
作者:
李梓晗; 刘园桥; 司道远
130033 长春,吉林大学中日联谊医院心血管内科
Author(s):
-
关键词:
心力衰竭; 甲状腺激素; 亚临床甲状腺功能减退; 低T3综合征; 激素替代治疗
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.02.008
文献标识码:
-
摘要:
心力衰竭是一组由心脏结构和（或）功能异常引起的临床综合征。甲状腺功能减退已被证实与心力衰竭的发生、进展和不良预后密切相关。15%～30%的心力衰竭患者可出现血清三碘甲状腺原氨酸（T3）降低。有研究认为补充甲状腺激素可以改善心功能，但心力衰竭合并亚临床甲状腺功能减退或低T3综合征患者能否从替代治疗中获益尚存在争论。该文介绍补充甲状腺激素治疗心力衰竭的研究进展。
Abstract:
-

参考文献/References

[1] 《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究, 2022, 20 (7):577-596.
[2] Bielecka-Dabrowa A, Godoy B, Suzuki T, et al. Subclinical hypothyroidism and the development of heart failure: an overview of risk and effects on cardiac function[J]. Clin Res Cardiol, 2019, 108(3):225-233.
[3] Lisco G, De Tullio A, Iacoviello M, et al. Congestive heart failure and thyroid dysfunction: the role of the low T3 syndrome and therapeutic aspects[J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(5):646-653.
[4] Ord WM. On myx?dema, a term proposed to be applied to an essential condition in the "Cretinoid" affection occasionally observed in middle-aged women[J]. Med Chir Trans, 1878, 61:57-78. 55.
[5] Rastogi P, Dua A, Attri S, et al. Hypothyroidism-induced reversible dilated cardiomyopathy[J]. J Postgrad Med, 2018, 64(3):177-179.
[6] Rizzo C, Gioia MI, Parisi G, et al. Dysthyroidism and chronic heart failure: pathophysiological mechanisms and therapeutic approaches[J]. Adv Exp Med Biol, 2018, 1067:239-253.
[7] Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts[J]. Circulation, 2012, 126(9):1040-1049.
[8] Hyland KA, Arnold AM, Lee JS, et al. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study[J]. J Clin Endocrinol Metab, 2013, 98(2):533-540.
[9] Zhang Y, Zhang J, Butler J, et al. Contemporary epidemiology, management, and outcomes of patients hospitalized for Heart Failure in China: results from the China Heart Failure (China-HF) registry[J]. J Card Fail, 2017, 23 (12):868-875.
[10] De Matteis G, Covino M, Burzo ML, et al. Prognostic role of hypothyroidism and low free-triiodothyronine levels in patients hospitalized with acute heart failure[J]. Intern Emerg Med, 2021, 16(6):1477-1486.
[11] Cetin EH, Cetin MS, K?nte HC, et al. Lower levels of triiodothyronine are associated with poor hemodynamic profile and all-cause mortality in heart failure[J]. Biomark Med, 2021, 15(4):273-283.
[12] Sato Y, Yoshihisa A, Kimishima Y, et al. Low T3 syndrome is associated with high mortality in hospitalized patients with heart failure[J]. J Card Fail, 2019, 25(3):195-203.
[13] Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism:longitudinal study[J]. BMJ, 2019, 366:l4892.
[14] Iacoviello M, Parisi G, Gioia MI, et al. Thyroid disorders and prognosis in chronic heart failure: a long-term follow-up study[J]. Endocr Metab Immune Disord Drug Targets, 2020, 20(3):437-445.
[15] Vale C, Neves JS, von Hafe M, et al. The role of thyroid hormones in heart failure[J]. Cardiovasc Drugs Ther, 2019, 33(2):179-188.
[16] Takahashi H, Kashiwagi Y, Nagoshi T, et al. Low triiodothyronine levels correlate with high B-type natriuretic peptide levels in patients with heart failure[J]. Sci Rep, 2021, 11(1):21865.
[17] Fraczek-Jucha M, Zbierska-Rubinkiewicz K, Kabat M, et al. Low triiodothyronine syndrome and selenium deficiency—undervalued players in advanced heart failure? A single center pilot study[J]. BMC Cardiovasc Disord, 2019, 19(1):105.
[18] Zhao X, Zhang R, Jiang H, et al. Combined use of low T3 syndrome and NT-proBNP as predictors for death in patients with acute decompensated heart failure[J]. BMC Endocr Disord, 2021, 21(1):140.
[19] Wang X, Wang H, Li Q, et al. Effect of levothyroxine supplementation on the cardiac morphology and function in patients with subclinical hypothyroidism: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2022, 107(9):2674-2683.
[20] Dereli S, Bayramo?lu A, ?zer N, et al. Evaluation of left atrial volume and functions by real time three-dimensional echocardiography in patients with subclinical hypothyroidism before and after levothyroxine therapy[J]. Echocardiography, 2019, 36(5):916-923.
[21] Zhao T, Chen B, Zhou Y, et al. Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis[J]. BMJ Open, 2017, 7(10):e016053.
[22] Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial[J]. Ann Intern Med, 1984, 101(1):18-24.
[23] Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study)[J]. J Clin Endocrinol Metab, 2001, 86(10):4860-4866.
[24] Razvi S, Ingoe L, Keeka G, et al. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial[J]. J Clin Endocrinol Metab, 2007, 92(5):1715-1723.
[25] Curotto Grasiosi J, Peressotti B, Machado RA, et al. Improvement in functional capacity after levothyroxine treatment in patients with chronic heart failure and subclinical hypothyroidism[J]. Endocrinol Nutr, 2013, 60(8):427-432.
[26] 曹昌强. 左甲状腺素钠治疗慢性心力衰竭合并亚临床甲状腺功能减退的临床疗效研究[J]. 基层医学论坛, 2020, 24(35):5093-5094．
[27] Zhang X, Wang WY, Zhang K, et al. Efficacy and safety of levothyroxine (L-T4) replacement on the exercise capability in chronic systolic heart failure patients with subclinical hypothyroidism: study protocol for a multi-center, open label, randomized, parallel group trial (ThyroHeart-CHF)[J]. Trials, 2019, 20(1):143.
[28] Ehrenkranz J, Bach PR, Snow GL, et al. Circadian and circannual rhythms in thyroid hormones: determining the TSH and free T4 reference intervals based upon time of day, age, and sex[J]. Thyroid, 2015, 25(8):954-961.
[29] Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2022, 79(17):e263-e421.
[30] Pearce SHS, Brabant G, Duntas LH, et al. 2013 ETA guideline:management of subclinical hypothyroidism[J]. Eur Thyroid J, 2013, 2(4):215-228.
[31] Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association[J]. Endocr Pract, 2012, 18(6):988-1028.
[32] 中华医学会内分泌学分会. 成人甲状腺功能减退症诊治指南[J]. 中华内分泌代谢杂志, 2017, 33(2):167-180.
[33] Badran HM, Faheem N, Zidan A, et al. Effect of short-term L-thyroxine therapy on left ventricular mechanics in idiopathic dilated cardiomyopathy[J]. J Am Soc Echocardiogr, 2020, 33(10):1234-1244.
[34] Chen X, Bao Y, Shi C, et al. Effectiveness and safety of thyroid hormone therapy in patients with dilated cardiomyopathy:a systematic review and meta-analysis of RCTs[J]. Am J Cardiovasc Drugs, 2022, 22(6):647-656.
[35] Pingitore A, Galli E, Barison A, et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study[J]. J Clin Endocrinol Metab, 2008, 93(4):1351-1358.
[36] Amin A, Chitsazan M, Taghavi S, et ak. Effects of triiodothyronine replacement therapy in patients with chronic stable heart failure and low-triiodothyronine syndrome: a randomized, double-blind, placebo-controlled study[J]. ESC Heart Fail, 2015, 2(1):5-11.
[37] Shi C, Bao Y, Chen X, et al. The effectiveness of thyroid hormone replacement therapy on heart failure and low-triiodothyronine syndrome: an updated systematic review and meta-analysis of randomized controlled trials[J]. Endocr Pract, 2022, 28(11):1178-1186.
[38] Holmager P, Schmidt U, Mark P, et al. Long-term L-triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study[J]. Clin Endocrinol (Oxf), 2015, 83(6):931-937.

备注/Memo

备注/Memo:
基金项目：吉林省科技发展计划基金（20200801076GH）
通信作者：司道远， E-mail：sidaoyuan@jlu.edu.cn
更新日期/Last Update: 2024-03-25